scholarly journals Pretreatment Neutrophil-Lymphocyte Ratio as a Predictor in Bladder Cancer and Metastatic or Unresectable Urothelial Carcinoma Patients: a Pooled Analysis of Comparative Studies

2018 ◽  
Vol 46 (4) ◽  
pp. 1352-1364 ◽  
Author(s):  
Shuiqing Wu ◽  
Xiaokun Zhao ◽  
Yinhuai Wang ◽  
Zhaohui Zhong ◽  
Lei Zhang ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Cancer Patients ◽  
Pooled Analysis ◽  
Risk Indicator ◽  
Advanced Tumor Stage ◽  
Free Survival ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Advanced Tumor

Background/Aims: Emerging studies have shown that the neutrophil-lymphocyte ratio (NLR) is a potential predictor in various tumors. Our study was conducted to assess the prognostic value of the pretreatment NLR in bladder cancer and metastatic or unresectable urothelial carcinoma (mUC or uUC) patients up to July 2017. The correlation between the pretreatment NLR and pathological characteristics was also evaluated in bladder cancer patients. Methods: The hazard ratio (HR) and odds ratio (OR) with the 95% confidence interval (CI) were extracted or calculated from the included studies for further pooled analysis. A total of 21 studies were included in a pooled analysis. Results: The pooled results indicated that a high pretreatment NLR was associated with reduced overall survival (OS) (HR=1.27, 95% CI=1.12-1.43), relapse-free survival (RFS) (HR=1.41, 95% CI=1.23-1.60), progression-free survival (PFS) (HR=1.75, 95% CI=1.36-2.15), disease-specific survival (DSS) and cancer-specific survival (CSS) (HR=1.27, 95% CI=1.19-1.35) in the bladder cancer patients. Additionally, an elevated pretreatment NLR suggested a worse OS rate in the mUC or uUC patients (HR=1.63, 95% CI=1.34-1.91). The pooled ORs and 95% CIs showed that a high pretreatment NLR could be a risk indicator for certain pathological features, such as lymphovascular invasion, a positive margin status and advanced tumor stage. Conclusions: our results showed that a high pretreatment NLR predicted poor prognosis in bladder cancer, mUC and uUC patients.

scholarly journals Enhancing the Accuracy of Platelet to Lymphocyte Ratio after Adjustment for Large Platelet Count: A Pilot Study in Breast Cancer Patients

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Charalampos Seretis ◽  
Fotios Seretis ◽  
Emmanuel Lagoudianakis ◽  
Marianna Politou ◽  
George Gemenetzis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Platelet Count ◽  
Cancer Patients ◽  
Ductal Carcinoma ◽  
Advanced Tumor Stage ◽  
Breast Cancer Patients ◽  
Platelet To Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Advanced Tumor ◽  
Large Platelet

Background. The objective of our study is to investigate the potential effect of adjusting preoperative platelet to lymphocyte ratio, an emerging biomarker of survival in cancer patients, for the fraction of large platelets.Methods. A total of 79 patients with breast neoplasias, 44 with fibroadenomas, and 35 with invasive ductal carcinoma were included in the study. Both conventional platelet to lymphocyte ratio (PLR) and the adjusted marker, large platelet to lymphocyte ratio (LPLR), were correlated with laboratory and histopathological parameters of the study sample.Results. LPLR elevation was significantly correlated with the presence of malignancy, advanced tumor stage, metastatic spread in the axillary nodes and HER2/neu overexpression, while PLR was only correlated with the number of infiltrated lymph nodes.Conclusions. This is the first study evaluating the effect of adjustment for large platelet count on improving PLR accuracy, when correlated with the basic independent markers of survival in a sample of breast cancer patients. Further studies are needed in order to assess the possibility of applying our adjustment as standard in terms of predicting survival rates in cancer.

scholarly journals Preoperative fibrinogen-to-prealbumin ratio and neutrophil lymphocyte ratio/prealbumin ratio versus platelet distribution width-to-platelet count ratio as a prognostic predictor for bladder cancer

2021 ◽  
Author(s):  
jiacheng wu ◽  
Baoqian Zhai ◽  
Tao Li ◽  
Xiaolin Wang
Keyword(s):  
Bladder Cancer ◽  
Multivariate Analysis ◽  
Platelet Count ◽  
Cancer Patients ◽  
Platelet Distribution Width ◽  
Distribution Width ◽  
Cox Regression Analysis ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Count Ratio

Abstract Background Evidence indicates that preoperative fibrinogen/prealbumin (FPR), neutrophil lymphocyte ratio/prealbumin ratio (NLR/PA) and platelet distribution width-to-platelet count ratio (PDW/PLT) possess prognostic potential in numerous malignancies. However, their roles in bladder cancer remain unclear. In this study, we investigated the association between FPR, NLR/PA versus PDW/PLT and the prognosis in bladder cancer patients. Methods The clinical data of 147 patients with bladder cancer treated in Nantong cancer hospital from January 2009 to August 2014 were retrospectively analyzed. According to ROC curve, the optimal critical value of FPR, NLR/PA and PDW/PLT were 0.1084, 0.1045 and 0.1210 respectively. The patients were followed up for 5 years to observe the survival of the patients, and the clinicopathological data were statistically analyzed. Cox regression analysis was used for univariate and multivariate analysis. Finally, on this basis, the nomogram is constructed for internal verification. Results All patients were followed up for 5 years. A total of 102 patients survived with a survival rate of 69.4%, 45 patients died with a mortality rate of 30.6%. Further stratified analysis showed that the group with low FPR, low NLR/PA and low PDW/PLT had the best prognosis, while the group with high FPR, high NLR/PA and high PDW/PLT had the worst prognosis. Cox multivariate analysis showed that preoperative FPR, NLR/PA and PDW/PLT were independent risk factors for tumor progression (p = 0.007, p = 0.013, p = 0.000). The decrease of FPR, NLR/PA and PDW/PLT can significantly prolong OS and PFS in patients with bladder cancer. In internal validation, the c-index of the nomogram was 0.8140 (95% CI: 0.7577–0.8703). Conclusions Preoperative FPR and NLR/PA versus PDW/PLT can be an independent prognostic factor in bladder cancer patients and are associated with clinicopathological characteristics. They have a specific value in assessing the prognosis of bladder cancer patients.

scholarly journals Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Shinji Ohtake ◽  
Takashi Kawahara ◽  
Ryo Kasahara ◽  
Hiroki Ito ◽  
Kimito Osaka ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Patients ◽  
Progression Free Survival ◽  
Neutrophil To Lymphocyte Ratio ◽  
Prognostic Impact ◽  
Free Survival ◽  
Lymphocyte Ratio ◽  
Kaplan Meier ◽  
Advanced Bladder Cancer ◽  
Overall Mortality

Introduction and Objectives. Neutrophil-to-lymphocyte ratio (NLR) has been suggested to be a simple marker of the systemic inflammatory response in critical care patients. We previously assessed the utility of NLR as a biomarker to predict tumor recurrence and cancer death in bladder cancer patients who underwent radical cystectomy. In this study, we evaluated the prognostic impact of NLR in bladder cancer patients who received gemcitabine and nedaplatin (GN) chemotherapy.Methods. A total of 23 patients who received GN chemotherapy for advanced bladder cancer were enrolled in this study. The cut-off point of NLR according to the sensitivity and specificity levels was derived from the area under receiver operator characteristics (AUROC) curve plotted for disease progression or overall mortality.Results. The NLR cut-off point was determined as 4.14 for both tumor progression and overall mortality. Median progression-free survival (PFS)/overall survival (OS) in the higher NLR group (NLR ≥ 4.14) and lower NLR group (NLR < 4.14) were 194/468 days versus 73/237 days, respectively. Kaplan-Meier analysis showed that higher NLR significantly correlated with poorer PFS (p=0.011) and OS (p=0.045).Conclusions. NLR may serve as a new biomarker to predict responses to GN-based chemotherapy in advanced bladder cancer patients and/or their prognosis.

Nuclear and Cytoplasmic Expression of ErbB-4 in Prostate Cancer

2007 ◽  
Vol 22 (3) ◽  
pp. 181-185
Author(s):  
R. Ben-Yosef ◽  
D. Sarid ◽  
A. Vexler ◽  
G. Lidawi ◽  
M. Inbar ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Disease Free Survival ◽  
Tumor Stage ◽  
Lymph Node Involvement ◽  
Advanced Tumor Stage ◽  
Nuclear Staining ◽  
Free Survival ◽  
Advanced Tumor ◽  
Disease Free

Purpose To evaluate cytoplasmic and nuclear ErbB-4 expression in prostate cancer specimens and its association with outcome. Basic procedures Specimens of 50 prostate cancer patients were investigated for ErbB-4 overexpression using immunohistochemistry staining. Cytoplasmic and nuclear staining was graded as 0–3 according to its intensity. The prognostic parameters were tumor stage, PSA level, Gleason score, probability of positive lymph nodes (Partin's tables and Roach equation), and 5-year disease free survival (Kattan nomogram). Main findings Overexpression of ErbB-4 (≥1) was detected in 30 (60%) patients and overexpression using cytoplasmic and nuclear staining was ≥2 in 19 (38%) and 17 (34%) patients, respectively. In only one third of the specimens was there any similarity between the 2 types of staining. Advanced tumor stage, high pretreatment PSA levels and high Gleason scores were evenly distributed among the patients with low (≤1) and intermediate/high (≥2) ErbB-4 expression. The probability of lymph node involvement and 5-year disease free survival were similar in both types of staining. Principal conclusions ErbB-4 was overexpressed (cytoplasmic and nuclear staining) in approximately one third of prostate cancer patients. The rate of similarity between the 2 staining types was only 33%: overexpression was evenly distributed among intermediate/high and low risk prostate cancer patients with both staining methods.

scholarly journals Prognostic Function of Neutrophil-to-Lymphocyte Ratio in Patients with GEP-NEN: A Systematic Review and Meta-Analysis

2020 ◽  
Author(s):  
Yajie Wang ◽  
Bei Wen ◽  
Yuxin Zhang ◽  
Kangdi Dong ◽  
Shubo Tian ◽  
...  
Keyword(s):  
Systematic Review ◽  
Web Of Science ◽  
Meta Analysis ◽  
Pooled Analysis ◽  
Neutrophil To Lymphocyte Ratio ◽  
Neuroendocrine Neoplasm ◽  
Free Survival ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
The Relationship

Abstract Purpose: A high neutrophil-to-lymphocyte ratio (NLR) might be related to unfavorable prognosis. We sought to conduct a systematic review and meta-analysis of published studies exploring the relationship between NLR with the prognosis in patients with gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN).Methods: The databases PubMed, Embase, and Web of Science were searched using words like 'neutrophil lymphocyte ratio', neuroendocrine tumors', and others through May 2020. We evaluated the significance of NLR on overall survival (OS) and recurrence-free survival (RFS) of patients with GEP-NEN in our study.Results: We gathered thirteen cohorts with 1598 cases. The pooled analysis revealed that a higher NLR related to worse OS (hazards ratio (HR): 4.59, 95% confidence interval (CI) 3.35-6.29, P < 0.00001) and poor RFS (HR: 4.05, 95% CI: 2.78–5.90, P＜0.00001) in patients with GEP-NEN.Conclusion: A high NLR can be considered a high-risk prognostic factor in GEP-NEN.

Study of pre-operative neutrophil–lymphocyte ratio in urothelial carcinoma

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Kausalya Kumari Sahu ◽  
Madhurya Ramineni ◽  
Pooja K. Suresh ◽  
Jyoti R. Kini ◽  
Flora D. Lobo
Keyword(s):  
Urothelial Carcinoma ◽  
Univariate Analysis ◽  
Progression Free Survival ◽  
Pathological Stage ◽  
Tumour Stage ◽  
Tumour Grade ◽  
Cancer Specific Survival ◽  
Free Survival ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio

Abstract Objectives Neutrophil–lymphocyte ratio (NLR), as an indicator of heightened systemic inflammatory response, predicts increased disease burden and poor oncological outcomes in urothelial carcinoma (UC). The study was undertaken with an aim to evaluate the association of NLR with clinicopathological variables and survival outcomes. Methods A total of 80 patients of UC were enrolled in the current retrospective study. Pre-operative NLR (within one month prior to the procedure), patient age, sex, tumour grade, pathological stage, recurrence free survival (RFS), progression free survival (PFS) and cancer specific survival (CSS) were recorded. We chose a cut-off value of 2.7 for NLR and patients were divide into two groups (NLR <2.7 and ≥2.7). Results NLR ≥2.7 was significantly associated with advanced tumour stage (p=0.001), but not with tumour grade (p=0.116). Progression (p=0.032) and death rates (p=0.026) were high in patients with NLR ≥2.7. Mean RFS (p=0.03), PFS (p=0.04) and CSS (p=0.04) were reduced in patients with NLR ≥2.7. On univariate analysis, NLR ≥2.7 predicted worse RFS (HR=2.928, p=0.007), PFS (HR=3.180, p=0.006) and CSS (HR=3.109, p=0.016). However, it was not an independent predictor of outcomes on multivariate analysis. Conclusions Tumour stage and grade are the only independent predictors of RFS, PFS and CSS. High NLR at a cut-off value of ≥2.7 is associated with advanced pathological stage, but does not have an independent predictive value for RFS, PFS and CSS.

scholarly journals The Prognostic Significance of Combined Pretreatment Fibrinogen and Neutrophil-Lymphocyte Ratio in Various Cancers: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Rongqiang Liu ◽  
Shiyang Zheng ◽  
Qing Yuan ◽  
Peiwen Zhu ◽  
Biao Li ◽  
...  
Keyword(s):  
Prognostic Value ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
Regression Analyses ◽  
Free Survival ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Meta Regression

Purpose. The prognostic value of a new scoring system, termed F-NLR, that combines pretreatment fibrinogen level with neutrophil-lymphocyte ratio has been evaluated in various cancers. However, the results are controversial. The purpose of this study was to comprehensively analyze the prognostic value of F-NLR score in patients with cancers. Methods. An integrated search of relevant studies was conducted by screening the PubMed and Embase databases. Pooled hazard ratios, with 95% confidence intervals (CIs), for overall survival (OS) and disease-free survival (DFS)/progression-free survival (PFS) were calculated to estimate the prognostic significance of F-NLR score in patients with various tumors. A random effects model was used for comprehensive analysis, and subgroup and meta-regression analyses were used to explore sources of heterogeneity. Results. Thirteen articles reporting data from of 4747 patients were included in the study. Pooled analysis revealed that high F-NLR score was significantly associated with poor OS ( HR = 1.77 ; 95% CI, 1.51–2.08) and poor DFS/PFS ( HR = 1.63 ; 95% CI, 1.30–2.05). Subgroup and meta-regression analyses did not alter the prognostic role of F-NLR score in OS and DFS/PFS. Conclusions. Increased F-NLR score is significantly associated with poor prognosis in patients with cancers and can serve as an effective prognostic indicator.

scholarly journals Genetic Variants of lncRNA GAS5 Are Associated with the Clinicopathologic Development of Oral Cancer

2021 ◽  
Vol 11 (5) ◽  
pp. 348
Author(s):  
Ming-Hong Hsieh ◽  
Hsueh-Ju Lu ◽  
Chiao-Wen Lin ◽  
Chia-Yi Lee ◽  
Shang-Jung Yang ◽  
...  
Keyword(s):  
Cell Differentiation ◽  
Oral Cancer ◽  
Cancer Patients ◽  
Alcohol Drinking ◽  
Tumor Size ◽  
Genetic Variants ◽  
Tumor Stage ◽  
Advanced Tumor Stage ◽  
Advanced Tumor ◽  
Oral Cancer Patients

The long noncoding RNA, Growth arrest-specific 5 (GAS5) plays a crucial role in the development of oral cancer. However, potential genetic variants in GAS5 that affect the susceptibility and progression of oral cancer have rarely been explored. In this study, two loci of GAS5 single nucleotide polymorphisms (SNPs) (rs145204276 and rs55829688) were genotyped by using the TaqMan allelic discrimination in 1125 oral cancer patients and 1195 non-oral-cancer individuals. After statistical analyses, the distribution of both the GAS5 SNP rs145204276 and GAS5 SNP rs55829688 frequencies were similar between the study and control groups. However, the patients with GAS5 SNP rs145204276 variants (Ins/Del or Del/Del) showed a higher tendency of moderate to poor cell differentiation of oral cancer (OR: 1.454, 95% CI: 1.041–2.031, p = 0.028). Moreover, the GAS5 SNP rs145204276 variants (Ins/Del or Del/Del) in the non-alcohol-drinking population were associated with significantly advanced tumor stage (OR: 1.500, 95% CI: 1.081–2.081, p = 0.015) and larger tumor size (OR: 1.494, 95% CI: 1.076–2.074, p = 0.016). Furthermore, individuals with the GAS5 SNP rs145204276 variant were associated with a higher expression of GAS5 in the GTEx database (p = 0.002), and the higher GAS5 level was associated with poor cell differentiation, advanced tumor stage and larger tumor size in head and neck squamous cell carcinoma from the TCGA database (all p < 0.05). In conclusion, the GAS5 SNP rs145204276 variant is related to poor-differentiation cell status in oral cancer. Besides, the presence of the GAS5 SNP rs145204276 variant is associated with a worse tumor stage and tumor size in oral cancer patients without alcohol drinking.

Sign in / Sign up

Export Citation Format

Share Document